1305 related articles for article (PubMed ID: 18383518)
1. Functional imaging of neuroendocrine tumors with combined PET/CT using 68Ga-DOTATATE (DOTA-DPhe1,Tyr3-octreotate) and 18F-FDG.
Kayani I; Bomanji JB; Groves A; Conway G; Gacinovic S; Win T; Dickson J; Caplin M; Ell PJ
Cancer; 2008 Jun; 112(11):2447-55. PubMed ID: 18383518
[TBL] [Abstract][Full Text] [Related]
2. Comparison of the Impact of 68Ga-DOTATATE and 18F-FDG PET/CT on Clinical Management in Patients with Neuroendocrine Tumors.
Panagiotidis E; Alshammari A; Michopoulou S; Skoura E; Naik K; Maragkoudakis E; Mohmaduvesh M; Al-Harbi M; Belda M; Caplin ME; Toumpanakis C; Bomanji J
J Nucl Med; 2017 Jan; 58(1):91-96. PubMed ID: 27516446
[TBL] [Abstract][Full Text] [Related]
3. A comparison of 68Ga-DOTATATE and 18F-FDG PET/CT in pulmonary neuroendocrine tumors.
Kayani I; Conry BG; Groves AM; Win T; Dickson J; Caplin M; Bomanji JB
J Nucl Med; 2009 Dec; 50(12):1927-32. PubMed ID: 19910422
[TBL] [Abstract][Full Text] [Related]
4. MIB-1 Index-Stratified Assessment of Dual-Tracer PET/CT with
Sampathirao N; Basu S
J Nucl Med Technol; 2017 Mar; 45(1):34-41. PubMed ID: 28154019
[TBL] [Abstract][Full Text] [Related]
5. Can complementary 68Ga-DOTATATE and 18F-FDG PET/CT establish the missing link between histopathology and therapeutic approach in gastroenteropancreatic neuroendocrine tumors?
Has Simsek D; Kuyumcu S; Turkmen C; Sanlı Y; Aykan F; Unal S; Adalet I
J Nucl Med; 2014 Nov; 55(11):1811-7. PubMed ID: 25315243
[TBL] [Abstract][Full Text] [Related]
6. Comparison of 68Ga-DOTANOC and 68Ga-DOTATATE PET/CT within patients with gastroenteropancreatic neuroendocrine tumors.
Wild D; Bomanji JB; Benkert P; Maecke H; Ell PJ; Reubi JC; Caplin ME
J Nucl Med; 2013 Mar; 54(3):364-72. PubMed ID: 23297077
[TBL] [Abstract][Full Text] [Related]
7. Comparison of
Yu HN; Liu L; Chen QS; He Q; Li YS; Wang Y; Gao S
Orthop Surg; 2021 May; 13(3):791-798. PubMed ID: 33709632
[TBL] [Abstract][Full Text] [Related]
8. Dual tracer functional imaging of gastroenteropancreatic neuroendocrine tumors using 68Ga-DOTA-NOC PET-CT and 18F-FDG PET-CT: competitive or complimentary?
Naswa N; Sharma P; Gupta SK; Karunanithi S; Reddy RM; Patnecha M; Lata S; Kumar R; Malhotra A; Bal C
Clin Nucl Med; 2014 Jan; 39(1):e27-34. PubMed ID: 24217539
[TBL] [Abstract][Full Text] [Related]
9. Discordance Between Histopathologic Grading and Dual-Tracer PET/CT Findings in Metastatic NETs and Outcome of
Adnan A; Basu S
J Nucl Med Technol; 2022 Sep; 50(3):248-255. PubMed ID: 34876476
[TBL] [Abstract][Full Text] [Related]
10. Evaluation of neuroendocrine liver metastases: a comparison of dynamic contrast-enhanced magnetic resonance imaging and positron emission tomography/computed tomography.
Armbruster M; Sourbron S; Haug A; Zech CJ; Ingrisch M; Auernhammer CJ; Nikolaou K; Paprottka PM; Rist C; Reiser MF; Sommer WH
Invest Radiol; 2014 Jan; 49(1):7-14. PubMed ID: 24002080
[TBL] [Abstract][Full Text] [Related]
11. Clinical and Prognostic Value of PET/CT Imaging with Combination of
Zhang P; Yu J; Li J; Shen L; Li N; Zhu H; Zhai S; Zhang Y; Yang Z; Lu M
Contrast Media Mol Imaging; 2018; 2018():2340389. PubMed ID: 29681780
[TBL] [Abstract][Full Text] [Related]
12. Combined Quantification of
Lee H; Nakamoto R; Moore SE; Pantel AR; Eads JR; Aparici CM; Pryma DA
Acad Radiol; 2022 Sep; 29(9):1308-1316. PubMed ID: 34836776
[TBL] [Abstract][Full Text] [Related]
13. Performance of 177Lu-DOTATATE-based peptide receptor radionuclide therapy in metastatic gastroenteropancreatic neuroendocrine tumor: a multiparametric response evaluation correlating with primary tumor site, tumor proliferation index, and dual tracer imaging characteristics.
Thapa P; Ranade R; Ostwal V; Shrikhande SV; Goel M; Basu S
Nucl Med Commun; 2016 Oct; 37(10):1030-7. PubMed ID: 27243215
[TBL] [Abstract][Full Text] [Related]
14. Comparison of (18F)FDG PET/CT and (68Ga)DOTATATE PET/CT imaging methods in terms of detection of histological subtype and related SUVmax values in patients with pulmonary carcinoid tumors.
Komek H; Can C; Urakçi Z; Kepenek F
Nucl Med Commun; 2019 May; 40(5):517-524. PubMed ID: 30694875
[TBL] [Abstract][Full Text] [Related]
15. Comparison of ⁶⁸Ga-DOTATATE PET-CT, ¹⁸F-FDG PET-CT and 99mTc-(V)DMSA scintigraphy in the detection of recurrent or metastatic medullary thyroid carcinoma.
Ozkan ZG; Kuyumcu S; Uzum AK; Gecer MF; Ozel S; Aral F; Adalet I
Nucl Med Commun; 2015 Mar; 36(3):242-50. PubMed ID: 25369749
[TBL] [Abstract][Full Text] [Related]
16. A prospective head-to-head comparison of
Jiang Y; Liu Q; Wang G; Sui H; Wang R; Wang J; Zhu Z
Eur J Nucl Med Mol Imaging; 2022 Oct; 49(12):4218-4227. PubMed ID: 35657429
[TBL] [Abstract][Full Text] [Related]
17. Neuroendocrine Tumor Diagnosis and Management:
Sanli Y; Garg I; Kandathil A; Kendi T; Zanetti MJB; Kuyumcu S; Subramaniam RM
AJR Am J Roentgenol; 2018 Aug; 211(2):267-277. PubMed ID: 29975116
[TBL] [Abstract][Full Text] [Related]
18. (68)Ga-DOTATATE and (18)F-FDG PET/CT in Paraganglioma and Pheochromocytoma: utility, patterns and heterogeneity.
Chang CA; Pattison DA; Tothill RW; Kong G; Akhurst TJ; Hicks RJ; Hofman MS
Cancer Imaging; 2016 Aug; 16(1):22. PubMed ID: 27535829
[TBL] [Abstract][Full Text] [Related]
19. Quantitative and qualitative intrapatient comparison of 68Ga-DOTATOC and 68Ga-DOTATATE: net uptake rate for accurate quantification.
Velikyan I; Sundin A; Sörensen J; Lubberink M; Sandström M; Garske-Román U; Lundqvist H; Granberg D; Eriksson B
J Nucl Med; 2014 Feb; 55(2):204-10. PubMed ID: 24379222
[TBL] [Abstract][Full Text] [Related]
20. Neuroendocrine tumor recurrence: diagnosis with 68Ga-DOTATATE PET/CT.
Haug AR; Cindea-Drimus R; Auernhammer CJ; Reincke M; Beuschlein F; Wängler B; Uebleis C; Schmidt GP; Spitzweg C; Bartenstein P; Hacker M
Radiology; 2014 Feb; 270(2):517-25. PubMed ID: 24056402
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
